A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →. With Astellas Pharma Inc.
Phase
—
Status
Completed
Study type
Observational
Enrollment
1,300actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-21 | actual | When the study began enrolling |
| Primary completion | 2025-10-31 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-10-31 | actual | The whole study's end, after follow-up |
| First posted | 2025-07-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Metastatic Castration Sensitive Prostate Cancer (mCSPC)
- Cancer of the Prostate
- Prostate Neoplasms
- Prostate Cancer
Interventions
- Drug: Enzalutamide — also filed as XTANDI
- Drug: Apalutamide — also filed as ERLEADA
Primary outcome
what the primary-completion date above is the date OFTreatment duration
measured Up to approximately 65 months
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed